Respiratory Pathogen Panel (RPP)

Respiratory infections are caused by both bacteria and viruses located in the upper and lower respiratory tracts of patients. These infections produce many common clinical symptoms such as:

Upper Respiratory Tract Infections (URTI)

  • Rhinitis
  • Sinusitis
  • Pertussis
  • Laryngitis
  • Pharyngitis
  • Influenza
  • Infectious Mononucleosis

Lower Respiratory Tract Infections (LRTI)

  • Pneumonia
  • Bronchitis
  • Bronchiolitis
  • Pleuritis
  • Empyema

Acute respiratory infection is a significant cause of morbidity and mortality in young, geriatric and immunocompromised patients. Co-infection is also high within these populations and access to advanced technology is essential to detect multiple pathogens at once. False negative test results can lead to a delayed diagnosis and poor clinical outcomes.

Innovative Gx Laboratories’ Respiratory Pathogen Panel (RPP) is a molecular diagnostic test that will rapidly identify a wide range of respiratory pathogens using both Polymerase Chain Reaction (PCR) and Reverse Transcription Polymerase Chain Reaction (RT PCR). Both PCR and RT-PCR technologies precisely identify the correct pathogen(s) present in the infection and will also detect antibiotic drug resistance contained in the pathogen.

  • Provides a more definitive diagnosis than point-of-care antigen assays
  • 24-hour turnaround from specimen receipt
  • More accurate, without the wait times of conventional culture
  • CAP accredited laboratory

Helps improve clinical confidence and decrease patient risks

  • Detects polymicrobial infections
  • Unaffected by concurrent antibiotic use
  • Identifies potential antibiotic resistance
  • Aids in quick clinical decision-making
  • Reduces false negative results
  • Aids in antibiotic stewardship
  • Reduces potential unnecessary drug exposure and adverse events

Upper Respiratory


  • Bordetella pertussis
  • Haemophilus influenzae
  • Mycoplasma pneumoniae
  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • Streptococcus pneumoniae
  • Streptococcus pyogenes (Group A)


  • Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43
  • Human Bocavirus (HBoV)
  • Influenza A
  • Influenza B
  • Metapneumovirus
  • Parainfluenza Virus 1/2/3
  • Parainfluenza Virus 4
  • Respiratory Syncytial Virus A
  • Rhinovirus 1


  • Candida albicans
  • Candida dubliniensis
  • andida parapsilosis
  • andida tropicalis

Lower Respiratory


  • Bordetella pertussis
  • Chlamydophila pneumoniae
  • Haemophilus influenzae
  • Legionella pneumophila
  • Moraxella catarrhalis
  • Mycobacterium kansasii and intracellulare
  • Mycobacterium tuberculosis
  • Mycoplasma pneumoniae
  • Streptococcus pneumoniae


  • Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43
  • Influenza A
  • Influenza B
  • Metapneumovirus
  • Respiratory Syncytial Virus A
  • Rhinovirus 1

Antibiotic Resistance

  • Carbapenemase and Metallo-Betalactamase Resistance
  • Class A and C Beta-lactams Resistance
  • Class A and Plasmid ESBL Resistance
  • Class C Beta-lactams Resistance
  • Class D Beta-lactamase Resistance
  • Dihydrofolate and Sulfonamide Resistance
  • Macrolide Resistance
  • Methicillin Resistance
  • Quinolone Resistance
  • Tetracycline Resistance

The Innovative Gx Laboratories’ Molecular Respiratory Pathogen Test (RPP) quickly identifies pathogens and detects potential antibiotic resistance so that effective treatment can begin sooner.